Our funds
The fund

Fondita Healthcare is an actively managed, global healthcare fund. In line with the Article 9 sustainability rating, the fund’s social sustainability objective is to invest in companies that promote health and well-being, as well as access to healthcare and equality in their own business operations.

Healthcare

The fund invests in companies that address current and unmet medical needs and provide access to medicine and medical care. This is achieved by investing in companies active in innovation, production and distribution of medicines and healthcare equipment, tools and supplies as well as diagnostics and healthcare services. Operationally, the companies are to act in a socially and environmentally responsible way.

Healthcare is an incredibly interesting, structurally growing sector and one of the three megatrends that Fondita’s thematic funds invest in.

Demographic changes with an ageing population, as well as increased welfare, translate into growing demand for healthcare. Innovation and technological advances improve care and deliver new products to fulfil current and unmet demand fueling the sector’s growth.

Sustainability
Read more about the fund’s sustainability principles:

Portfolio managers

Marcus Björkstén

Portfolio Manager, Head of Portfolio Management
Fund facts

30.9.2026

Fund size (M€)
11,6
ISIN (A)
FI4000321088
ISIN (B)
FI4000321096
Currency
EUR
Management fee
2,00 % p.a.
Risk indicator
4/7
SFDR Classification
Article 9
The fund manager's comment
September was characterised by rising energy prices and sharply higher long-term interest rates, creating headwinds for global equity markets. Higher energy prices fuelled inflation concerns, while the continued resilience of the US economy reinforced expectations that monetary policy would remain restrictive. Despite these headwinds, strong earnings growth and continued A...
Top holdings
Eli Lilly & Co (US)
9,7 %
Novartis (CH)
5,1 %
Merck & Co (US)
4,9 %
Unitedhealth Group (US)
4,6 %
AstraZeneca (SE)
4,5 %
USA
46 %
Switzerland
15 %
Sweden
12 %
Denmark
7 %
Belgium
7 %
Return
1 month
-1,7 %
3 months
1,3 %
6 months
5,9 %
YTD
-3,2 %
1 year
3,4 %
3 years
5,0 %
5 years
-13,9 %
since launch (14.6.2018)
41,6 %
since launch p.a.
4,3 %
Sector division
Pharma
64 %
Equipment
35 %
Cash
1 %
Top 10 holdings
Eli Lilly & Co (US)
9,7 %
Novartis (CH)
5,1 %
Merck & Co (US)
4,9 %
Unitedhealth Group (US)
4,6 %
AstraZeneca (SE)
4,5 %
Novo Nordisk (DK)
4,0 %
Medtronic (US)
3,9 %
Boston Scientific (US)
3,8 %
Medicover (SE)
3,7 %
Jazz Pharmaceuticals (US)
3,6 %
Country division
USA
46 %
Switzerland
15 %
Sweden
12 %
Denmark
7 %
Belgium
7 %
Germany
4 %
Other
9 %
Currency exposure
USD
46 %
EUR
16 %
CHF
15 %
SEK
12 %
DKK
7 %
GBP
3 %
Fees
TER
2,00 %
Subscription fee
0,00 %
Redemption fee
0,00 %

Total client relationship allow for changes in tariff rate.

Documents

FUND INFORMATION
KID
PAI Statements
Fund rules
KID DE
KID I DE
Prospectus
REPORTS
Monthly report
Annual report
Semi-annual report
SUSTAINABILITY DOCUMENTS
ESG Report
Shared sustainability documents
Sustainability-related disclosures

This is marketing communication. The past performance of the investment fund does not provide any guarantee of future results. Read the fund prospectus and KID (Key Information Document) before making any investment decisions. The fund prospectus and KID are available on English, Finnish and Swedish at our website.

Our funds
Latest news
20 years of Nordic micro caps

In September 2006, after ten years of investing in Nordic small caps, we launched Fondita Nordic Micro Cap, the first fund dedicated ... Read more

Notes from Silicon Valley

I was excited to be back in Silicon Valley again this year. Danske Bank had set up an ambitious, high-quality meeting agenda ... Read more

This page was last updated

Web design: Wikström Media
Fondita online Fondita
online